Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor

Background: Hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer patients have had a wide range of therapeutical options since the incorporation of targeted therapies alongside classic chemotherapy. However, because of their disease, virtually all patients will...

Descripción completa

Detalles Bibliográficos
Autores principales: López de Sá, Alfonso, de Luna, Alicia, Antoñanzas, Mónica, García-Barberán, Vanesa, Moreno-Anton, Fernando, García-Sáenz, Jose A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755882/
https://www.ncbi.nlm.nih.gov/pubmed/36531075
http://dx.doi.org/10.3389/fonc.2022.997346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755882/
https://www.ncbi.nlm.nih.gov/pubmed/36531075
http://dx.doi.org/10.3389/fonc.2022.997346

Ejemplares similares